Regress Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-12-2024
- Paid Up Capital ₹ 0.10 M
as on 06-12-2024
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit 98.21%
(FY 2021)
- Ebitda 98.21%
(FY 2021)
- Net Worth -1.83%
(FY 2021)
- Total Assets -1.83%
(FY 2021)
About Regress Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sangeeta Billa and Arvind Billa serve as directors at the Company.
- CIN/LLPIN
U85121DL2006PTC152439
- Company No.
152439
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Aug 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Regress Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangeeta Billa  | Director | 24-Aug-2006 | Current |
| Arvind Billa | Director | 24-Aug-2006 | Current |
Financial Performance of Regress Lifesciences.
Regress Lifesciences Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 98.21% increase in profit. The company's net worth dipped by a decrease of 1.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Regress Lifesciences?
In 2021, Regress Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Affy Pharma Private LimitedActive 34 years 4 monthsSangeeta Billa and Arvind Billa are mutual person
Affy Parenterals Private LimitedActive 5 years 2 daysSangeeta Billa and Arvind Billa are mutual person
- Affy Synthetics Private LimitedActive 5 years 2 days
Sangeeta Billa and Arvind Billa are mutual person
- Affy Polymers Private LimitedActive 5 years 16 days
Sangeeta Billa and Arvind Billa are mutual person
- Affy Healthcare Private LimitedActive 19 years 9 months
Sangeeta Billa and Arvind Billa are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Regress Lifesciences?
Unlock and access historical data on people associated with Regress Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Regress Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Regress Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
